首页|Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody‐covered sirolimus‐eluting Combo stent?and the sirolimus‐eluting Orsiro stent

Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody‐covered sirolimus‐eluting Combo stent?and the sirolimus‐eluting Orsiro stent

扫码查看
Abstract Objectives To compare the efficacy and safety of the dual therapy CD34 antibody‐covered sirolimus‐eluting Combo stent (DTS) and the sirolimus‐eluting Orsiro stent (SES) in patients with and without diabetes mellitus (DM) included in the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X study. Background The incidence of target lesion failure (TLF) after treatment with modern drug‐eluting stents has been reported to be significantly higher in patients with DM when compared to patients without DM. Thus, whether the results from the SORT OUT X study apply to patients with and without DM remains unknown. Methods In total 3146 patients were randomized to stent implantation with DTS (n?=?1578; DM: n?=?279) or SES (n?=?1568; DM: n?=?271). The primary end point, TLF, was a composite of cardiac death, target‐lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 1 year. Results At 1 year, the rate of TLF was increased in the DTS group compared to the SES group, both among patients with DM (9.3% vs. 4.8%; risk difference: 4.5%; incidence rate ratio: 1.99, 95% confidence interval [CI]: 1.02–3.90) and without DM (5.7% vs. 3.5%; incidence rate ratio: 1.67, 95% CI: 1.15–2.42). The differences were mainly explained by higher rates of TLR. Conclusion Compared to the SES, the DTS was associated with an increased risk of TLF at 12 months in patients with and without DM. The differences were mainly explained by higher rates of TLR, whereas rates of cardiac death and target lesion MI did not differ significantly between the two stent groups in patients with or without DM.

diabetesrandomized controlled trialstent comparisontarget lesion failure

Lars Jakobsen、Evald H. Christiansen、Phillip Freeman、Johnny Kahlert、Karsten Veien、Michael Maeng、Bent Raungaard、Julia Ellert、Steen D. Kristensen、Martin K. Christensen、Christian J. Terkelsen、Troels Thim、Ashkan Eftekhari、Rebekka V. Jensen、Nicolaj B. St?ttrup、Anders Junker、Henrik S. Hansen、Lisette O. Jensen

展开 >

Department of Cardiology,Aarhus University Hospital

Department of Cardiology,Aalborg University Hospital

Department of Clinical Epidemiology,Aarhus University Hospital

Department of Cardiology,Odense University Hospital

展开 >

2022

Catheterization and cardiovascular interventions

Catheterization and cardiovascular interventions

SCI
ISSN:1522-1946
年,卷(期):2022.99(7)
  • 28